August 2012
-
The most intense discussions of Day 2 of RDD Europe occurred during an afternoon session on LABA and LABA/ICS postmarket trial design in which industry representatives differed with each other and with regulators over the… Read more . . .
-
According to reports, GlaxoSmithKline has invested an additional $6.7 million in Theravance, its partner in developing a number of inhaled asthma and COPD drugs. The purchase of common stock gives GSK approximately 19% of Theravance’s… Read more . . .
-
Steroid manufacturers Sterling S.r.l., located in Perugia, Italy, is now producing APIs for respiratory delivery using particle engineering technology supplied by Prosonix. A two-year collaboration between the two companies has resulted in a retrofit of… Read more . . .
-
At the kickoff of RDD Europe 2011 in Berlin, Peter Byron of co-organizer RDD provided some attendance figures to the assembled delegates, telling the crowd that they number 470 in all, with ~85% of attendees… Read more . . .
-
MicroDose Therapeutx has announced that it has achieved a milestone that “signals the successful incorporation of MicroDose’s DPI technology into a Novartis platform pulmonary device” and triggers a milestone payment from Novartis. The two companies… Read more . . .
-
A Phase 2 clinical trial of its bepotastine besilate nasal spray for the treatment of seasonal allergic rhinitis has demonstrated significantly significant improvement in total nasal symptoms compared to placebo, announced ISTA Pharmaceuticals. The study… Read more . . .
-
The US FDA has issued a letter informing stakeholders that it will not appeal a December 2010 ruling by the US Court of Appeals for the DC Circuit that the agency has no authority to… Read more . . .
-
Abstracts should be submitted electronically by September 15, 2011 to: grace@bitlifesciences.com. See complete poster guidelines. Read more . . .
-
Gateway Analytical, a subsidiary of ChemImage Corporation, held a grand opening celebration at its new facility in Gibsonia, Pennsylvania on April 12, 2011. The 3,000-sq ft cGMP facility actually opened for business in October, 2010,… Read more . . .
-
A growing pharmaceutical company specializing in inhaled drug products is seeking a BS/MS level scientist with a background in inhalation or nasal formulation. They must be adept at solving complex problems and independently identifying problems.… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.